324 related articles for article (PubMed ID: 24994714)
1. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis.
Chou CC; Lee KH; Lai IL; Wang D; Mo X; Kulp SK; Shapiro CL; Chen CS
Cancer Res; 2014 Sep; 74(17):4783-95. PubMed ID: 24994714
[TBL] [Abstract][Full Text] [Related]
2. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator.
Lee KH; Hsu EC; Guh JH; Yang HC; Wang D; Kulp SK; Shapiro CL; Chen CS
J Biol Chem; 2011 Nov; 286(45):39247-58. PubMed ID: 21917926
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of scaffold/matrix attachment region-binding protein 1 (SMAR1) in breast cancer cells.
Adhikary A; Chakraborty S; Mazumdar M; Ghosh S; Mukherjee S; Manna A; Mohanty S; Nakka KK; Joshi S; De A; Chattopadhyay S; Sa G; Das T
J Biol Chem; 2014 Sep; 289(37):25431-44. PubMed ID: 25086032
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1α and FOXO3a by AMPK signaling.
Kim JH; Lee JO; Kim N; Lee HJ; Lee YW; Kim HI; Kim SJ; Park SH; Kim HS
Int J Oncol; 2015 Nov; 47(5):1874-80. PubMed ID: 26397839
[TBL] [Abstract][Full Text] [Related]
5. Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter.
Banerjee P; Surendran H; Chowdhury DR; Prabhakar K; Pal R
J Mol Med (Berl); 2016 Dec; 94(12):1397-1409. PubMed ID: 27534967
[TBL] [Abstract][Full Text] [Related]
6. Mouse double minute 2 (MDM2) upregulates Snail expression and induces epithelial-to-mesenchymal transition in breast cancer cells in vitro and in vivo.
Lu X; Yan C; Huang Y; Shi D; Fu Z; Qiu J; Yin Y
Oncotarget; 2016 Jun; 7(24):37177-37191. PubMed ID: 27184007
[TBL] [Abstract][Full Text] [Related]
7. Insulin receptor substrate 2 and FoxO3a signalling are involved in E-cadherin expression and transforming growth factor-β1-induced repression in kidney epithelial cells.
Carew RM; Browne MB; Hickey FB; Brazil DP
FEBS J; 2011 Sep; 278(18):3370-80. PubMed ID: 21777391
[TBL] [Abstract][Full Text] [Related]
8. Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade.
Yung MM; Chan DW; Liu VW; Yao KM; Ngan HY
BMC Cancer; 2013 Jul; 13():327. PubMed ID: 23819460
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of miR-21 reverses epithelial-mesenchymal transition and cancer stem cell phenotype through AKT/ERK1/2 inactivation by targeting PTEN.
Han M; Liu M; Wang Y; Chen X; Xu J; Sun Y; Zhao L; Qu H; Fan Y; Wu C
PLoS One; 2012; 7(6):e39520. PubMed ID: 22761812
[TBL] [Abstract][Full Text] [Related]
10. Metformin suppresses expression of the selenoprotein P gene via an AMP-activated kinase (AMPK)/FoxO3a pathway in H4IIEC3 hepatocytes.
Takayama H; Misu H; Iwama H; Chikamoto K; Saito Y; Murao K; Teraguchi A; Lan F; Kikuchi A; Saito R; Tajima N; Shirasaki T; Matsugo S; Miyamoto K; Kaneko S; Takamura T
J Biol Chem; 2014 Jan; 289(1):335-45. PubMed ID: 24257750
[TBL] [Abstract][Full Text] [Related]
11. FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells.
Liu H; Yin J; Wang H; Jiang G; Deng M; Zhang G; Bu X; Cai S; Du J; He Z
Cell Signal; 2015 Mar; 27(3):510-8. PubMed ID: 25578861
[TBL] [Abstract][Full Text] [Related]
12. DNMT3B overexpression by deregulation of FOXO3a-mediated transcription repression and MDM2 overexpression in lung cancer.
Yang YC; Tang YA; Shieh JM; Lin RK; Hsu HS; Wang YC
J Thorac Oncol; 2014 Sep; 9(9):1305-15. PubMed ID: 25122426
[TBL] [Abstract][Full Text] [Related]
13. Opposite regulation of MDM2 and MDMX expression in acquisition of mesenchymal phenotype in benign and cancer cells.
Slabáková E; Kharaishvili G; Smějová M; Pernicová Z; Suchánková T; Remšík J; Lerch S; Straková N; Bouchal J; Král M; Culig Z; Kozubík A; Souček K
Oncotarget; 2015 Nov; 6(34):36156-71. PubMed ID: 26416355
[TBL] [Abstract][Full Text] [Related]
14. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
15. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.
Chen J; Gomes AR; Monteiro LJ; Wong SY; Wu LH; Ng TT; Karadedou CT; Millour J; Ip YC; Cheung YN; Sunters A; Chan KY; Lam EW; Khoo US
PLoS One; 2010 Aug; 5(8):e12293. PubMed ID: 20808831
[TBL] [Abstract][Full Text] [Related]
16. Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.
Esparza-López J; Alvarado-Muñoz JF; Escobar-Arriaga E; Ulloa-Aguirre A; de Jesús Ibarra-Sánchez M
BMC Cancer; 2019 Jul; 19(1):728. PubMed ID: 31337349
[TBL] [Abstract][Full Text] [Related]
17. Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells.
Belguise K; Guo S; Sonenshein GE
Cancer Res; 2007 Jun; 67(12):5763-70. PubMed ID: 17575143
[TBL] [Abstract][Full Text] [Related]
18. AMP-activated protein kinase enhances the expression of muscle-specific ubiquitin ligases despite its activation of IGF-1/Akt signaling in C2C12 myotubes.
Tong JF; Yan X; Zhu MJ; Du M
J Cell Biochem; 2009 Oct; 108(2):458-68. PubMed ID: 19639604
[TBL] [Abstract][Full Text] [Related]
19. Nimotuzumab inhibits epithelial-mesenchymal transition in prostate cancer by targeting the Akt/YB-1/AR axis.
Hu S; Duan YX; Zhou Q; Wang Y; Lu Q
IUBMB Life; 2019 Jul; 71(7):928-941. PubMed ID: 30907986
[TBL] [Abstract][Full Text] [Related]
20. Nesfatin-1/Nucleobindin-2 enhances cell migration, invasion, and epithelial-mesenchymal transition via LKB1/AMPK/TORC1/ZEB1 pathways in colon cancer.
Kan JY; Yen MC; Wang JY; Wu DC; Chiu YJ; Ho YW; Kuo PL
Oncotarget; 2016 May; 7(21):31336-49. PubMed ID: 27150059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
